MFMichael D. Faulx

Michael D. Faulx

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael D. Faulx has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elucidating physiologic influences of sleep-related breathing and architectural disruption in Takotsubo syndrome

    by Sepideh Khazaie, Michael D. Faulx, James F. Bena, Shannon L. Morrison, Alex Milinovich, Megan Sheehan, Lu Wang, Reena Mehra

    Background: Takotsubo syndrome (TS), an acute stress-induced cardiomyopathy driven by catecholamine excess, shares pathophysiological features with sleep disordered breathing (SDB), yet this relationship remains unexplored. We hypothesize that SDB and sleep disruption influences TS risk and severity. Methods: We leveraged data from the Cleveland Clinic sleep cohort (1999–2021) including patients with proven TS and matched controls (1:5 ratio by age, sex, body mass index (BMI), and study year). Logistic regression models were used to assess odds of TS associated with SDB biomarkers, i.e., apnea-hypopnea index (AHI; evaluated at thresholds ≥ 5, ≥15, and ≥ 30), hypoxia (percentage of sleep time with SaO 2 n = 84; mean age 64.1 ± 11.4 years, 86.9% female, BMI 30.9 ± 7.7 kg/m 2 ) had higher comorbidity (e.g., 45.2% vs. 10.1% coronary artery disease, p < 0.001) and lower PAP use (17.9% vs. 43.0%, p < 0.001) compared to matched controls ( n = 414). Mild OSA (AHI 5–p = 0.032) and remained significant after adjustment for age, sex, BMI, comorbidities, and overall cardiovascular medication use (OR = 0.48, 95% CI 0.24–0.96, p = 0.037). In the subgroup analysis of patients with pre-TS sleep studies ( n = 36), a stronger association was observed for overall OSA (AHI ≥ 5) (OR = 0.34, 95% CI 0.13–0.91, p = 0.031). Arousal index correlated with lower LVEF in pre-TS cases (rho = − 0.40, p = 0.024). Moderate/severe OSA and hypoxia showed no significant association with TS. Conclusions: Mild OSA may be protective in TS, possibly via hypoxic preconditioning, while sleep fragmentation is associated with greater cardiac dysfunction. This first study of SDB in TS highlights a novel sleep-cardiac interplay, warranting further investigation.

  • Open Access

    Challenges in the Early Diagnosis, Screening and Management of Heart Failure in Patients with Chronic Obstructive Pulmonary Disease

    by Roop Kaw, Aniruddh S. Shah, Shashank Shekhar, Michael Faulx, Loutfi S. Aboussouan

    In patients with co-morbid CHF and COPD, the diagnosis of CHF can be delayed. It is also well known that left ventricular dysfunction can arise from progressive disease-related hyperinflation. Apart from the longitudinal risk of developing CHF in some patients, a short-term or subclinical risk of cardiac events has been reported after hospitalization for COPD exacerbation. Currently there are no data or strategies to support screening for the early diagnosis of CHF in patients with COPD. Similarly, pulmonary function testing results can also be confounding and inaccurate in establishing the severity of COPD during an active exacerbation of CHF. The hyperinflation of the lungs, which can alter LV geometry and mechanics, is at the root of many of the causes of LV underfilling, which eventually contributes to CHF. Conventional echocardiography can often miss subclinical myocardial dysfunction and hence make early diagnosis even more challenging. Advanced cardiac imaging modalities and revised echocardiographic parameters can help detect subclinical LV dysfunction and PH earlier, but there are no clinical outcome data to validate their routine use in day-to-day clinical practice. Beta-blockers are generally regarded as safe to be used for appropriate cardiovascular indications in patients with COPD, and recent trials have also established the safety of long-acting beta agonists for treating COPD in patients with elevated cardiac risk.

  • Open Access

    Giant Coronary Aneurysms

    by Ahmad T. Safdar, Joseph Sipko, Benjamin Yang, Tom Kai Ming Wang, Juan Pablo Umana, Michael Faulx

  • Open Access

    Jailed Right Coronary Artery Presenting With Recurrent Pulseless Electrical Activity Arrest

    by Eunice Dugan, Farah Abdulhai, Osamah Badwan, Christie Tang, Warren Skoza, E. Rene Rodriguez, Michael Faulx

  • Open Access

    Contemporary characteristics, outcomes and novel risk score for Takotsubo cardiomyopathy: a national inpatient sample analysis

    by Ankit Agrawal, Umesh Bhagat, Abdullah Yesilyaprak, Aqieda Bayat, Aanchal Sawhney, Aro Daniela Arockiam, Elio Haroun, Michael Faulx, Milind Y Desai, Wael Jaber, et al.

    Background Takotsubo cardiomyopathy (TC) is an established differential diagnosis of myocardial infarction with non-obstructive coronaries with significant interest but limited data on prognostication. We reviewed the characteristics and in-hospital outcomes and developed a novel risk score for TC. Methods Using the National Inpatient Sample data from 2016 to 2020, we identified adult patients (≥18 years) with acute coronary syndrome (ACS) and TC. We divided the cohort into ACS with and without TC and retrieved baseline data. Multivariable regression analysis was conducted to identify factors associated with TC diagnosis and adverse outcomes, leading to the development of a risk-scoring system. Results Among 7 219 004 adult ACS admissions, 78 214 (1.0%) were diagnosed with TC, with a mean age of 68.2 years, 64 526 (82.5%) being female and 5475 (7.0%, compared with 8.4% for other ACS) in-hospital mortality events. Factors significantly associated with TC were female sex (OR 6.78 (95% CI 6.47 to 7.09), pConclusions TC remains a high-risk diagnosis in a minority of ACS cases, with mortality rates similar to other ACS causes. Our novel risk score offers a valuable tool for risk stratification in patients with TC, but external validation is needed to confirm its utility.


  • Open Access

    Digoxin is still useful, but is still causing toxicity

    by Alejandro Durán Crane, Michael Militello, Michael D. Faulx

    Digoxin, the oldest known cardiovascular drug, is still used today to treat heart failure and atrial fibrillation. Because it has a narrow therapeutic index and multiple interactions, it frequently causes toxicity with a wide range of symptoms and cardiac arrhythmias. More importantly, elevated serum digoxin levels have been linked to a higher risk of death in patients with heart failure or atrial fibrillation, even without signs or symptoms of toxicity. This article reviews the current state of digoxin use, its pharmacologic principles, and the mechanisms, clinical presentation, and management of toxicity.


  • Open Access

    Sleep‐Disordered Breathing, Hypoxia, and Pulmonary Physiologic Influences in Atrial Fibrillation

    by Catherine M. Heinzinger, Nicolas R. Thompson, Alex Milinovich, Matheus Lima Diniz Araujo, Cinthya Pena Orbea, Nancy Foldvary‐Schaefer, Philippe Haouzi, Michael Faulx, David R. Van Wagoner, Mina K. Chung, et al.

    Background: We leverage a large clinical cohort to elucidate sleep‐disordered breathing and sleep‐related hypoxia in incident atrial fibrillation (AF) development given the yet unclear contributions of sleep‐related hypoxia and pulmonary physiology in sleep‐disordered breathing and AF. Methods and Results: Patients who underwent sleep studies at Cleveland Clinic January 2, 2000, to December 30, 2015, comprised this retrospective cohort. Cox proportional hazards models were used to examine apnea hypopnea index, percentage time oxygen saturation 2 , and 1947 (4.6%) developed AF over 5 years. A 10‐unit apnea hypopnea index increase was associated with 2% higher AF risk (hazard ratio [HR], 1.02 [95% CI, 1.00–1.03]). A 10‐unit increase in percentage time oxygen saturation <90% and 10‐unit decreases in mean and minimum oxygen saturation were associated with 6% (HR, 1.06 [95% CI, 1.04–1.08]), 30% (HR, 1.30 [95% CI, 1.18–1.42]), and 9% (HR, 1.09 [95% CI, 1.03–1.15]) higher AF risk, respectively. After adjustment for spirometry (n=9683 with available data), only hypoxia remained significantly associated with incident AF, although all coefficients were stable. Conclusions: Sleep‐related hypoxia was associated with incident AF in this clinical cohort, consistent across 3 measures of hypoxia, persistent after adjustment for pulmonary physiologic impairment. Findings identify a strong role for sleep‐related hypoxia in AF development without pulmonary physiologic interdependence.


  • Open Access

    Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists

    by Michael D. Faulx, Reena Mehra, Glaucylara Reis Geovanini, Shin-Ichi Ando, Michael Arzt, Luciano Drager, Michael Fu, Camilla Hoyos, Jo Hai, Juey-Jen Hwang, et al.


  • Open Access

    Obstructive Sleep Apnea and its Management in Patients with Atrial Fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT)) Global Survey of Practicing Cardiologists

    by Michael Faulx, Reena Mehra, Glaucylara Reis Geovanini, Shin-Ichi Ando, Michael Arzt, Luciano Drager, Michael Fu, Camilla M. Hoyos, Jo Hai, Juey-Jen Hwang, et al.

    Background: Among international cardiologists it is unclear whether equipoise exists regarding the benefit of diagnosing and managing obstructive sleep apnea (OSA) to improve atrial fibrillation (AF) outcomes and whether clinical practice and equipoise are linked. Methods: Between January 2019 and June 2020 we distributed a web-based 12-question survey regarding OSA and AF management to practicing cardiologists in 16 countries. Results: The United States, Japan, Sweden, and Turkey accounted for two-thirds of responses. 863 cardiologists responded; half were general cardiologists, a quarter electrophysiologists. Responses regarding treating OSA with CPAP to improve AF endpoints were mixed. 33% of respondents referred AF patients for OSA screening. OSA was diagnosed in 48% of referred patients and continuous positive airway pressure (CPAP) was prescribed for 59% of them. Nearly 70% of respondents believed randomized controlled trials (RCTs) of OSA treatment in AF patients were necessary and indicated willingness to contribute to such trials. Conclusions: There was no clinical equipoise among surveyed cardiologists; a majority expressed certainty that combined OSA and AF treatment is superior to AF treatment alone for improving AF outcomes. However, a minority of surveyed cardiologists referred AF patients for OSA testing, and while half of screened AF patients had OSA, CPAP was prescribed in little more than half of them, reflecting the view that better clinical trial evidence is needed to support this practice. Our results underscore the need for larger, multi-national prospective studies of OSA treatment and AF outcomes to inform more uniform society guideline recommendations.